Valeant in Deal to Buy Prostate-Cancer Drug Provenge From Dendreon
(NASDAQ/Dow Jones Business News) Jan 29, 2015 - Valeant Pharmaceuticals International Inc. said late Thursday it has reached a tentative deal to buy the prostate cancer drug Provenge and other assets from Dendreon Corp. for $296 million in cash.
read article »
Enzyme Inhibitor Shines in Polycythemia Vera Trial
(MedPage Today) Jan 29, 2015 - Significantly more patients with inadequately treated polycythemia vera (PCV) achieved protocol-defined disease control with the Janus kinase (JAK) inhibitor ruxolitinib (Jakavi) than with standard therapy, a phase III trial showed.
read article (free registration required) »
View ALL News »